IE
BRNS

Israel Englander’s Barinthus Biotherapeutics BRNS Stock Holding History

Israel Englander’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,960
Closed -$13.2K – 5884
2024
Q4 		$13.2K Buy
10,960
+812
+8% +$945 ﹤0.01% 5762
2024
Q3 		$12.5K Buy
+10,148
New +$13.6K ﹤0.01% 5847
2023
Q2 		– Sell
-41,945
Closed -$94K – 6135
2023
Q1 		$94K Buy
41,945
+1,557
+4% +$4.33K ﹤0.01% 5444
2022
Q4 		$97K Buy
40,388
+9,967
+33% +$25.4K ﹤0.01% 5594
2022
Q3 		$96K Sell
30,421
-30,974
-50% -$132K ﹤0.01% 5983
2022
Q2 		$273K Sell
61,395
-7,261
-11% -$35K ﹤0.01% 5442
2022
Q1 		$357K Sell
68,656
-2,287
-3% -$18.4K ﹤0.01% 5391
2021
Q4 		$788K Sell
70,943
-47,333
-40% -$597K ﹤0.01% 4633
2021
Q3 		$1.86M Sell
118,276
-11,861
-9% -$180K ﹤0.01% 4009
2021
Q2 		$2.18M Buy
+130,137
New +$1.93M ﹤0.01% 3856

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Israel Englander's BRNS Position: Q1 2025 in Review

Israel Englander sold out of Barinthus Biotherapeutics (BRNS) in Q1 2025, closing a stake of 10,960 shares — an estimated $13.2K sold.

Israel Englander first reported a position in BRNS in Q2 2021 and held it in 10 quarters. The position peaked at $2.18M in Q2 2021. 15 funds tracked by Wall St. Rank hold BRNS as of Q1 2025.

  • Israel Englander reported no remaining Barinthus Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Israel Englander sold 10,960 Barinthus Biotherapeutics shares in Q1 2025, an estimated $13.2K.
  • Israel Englander first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 10 quarters.
  • Israel Englander's Barinthus Biotherapeutics position peaked at $2.18M in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.